Abstract
With an advance in therapy, there are increasing emerging and re-emerging opportunistic infections among patients with hematologic conditions and malignancy. Herein, we present a 56-year-old woman with primary myelofibrosis who developed combined tuberculosis (TB) and cryptococcosis with extensive pulmonary, pleural, and nodal involvement during ruxolitinib therapy. Marked clinical and radiologic improvements were undoubtedly evident after receiving anti-TB and antifungal therapies and pleural drainage. Hence, the presence of atypical clinical and radiologic manifestations and incomplete responses, despite receiving adequate antimicrobial treatment, should raise concerns regarding the combined emerging and re-emerging opportunistic infections and the possibility of unusual radiologic manifestations of cryptococcosis in a ruxolitinib-treated patient.
| Original language | English |
|---|---|
| Pages (from-to) | 3901-3905 |
| Number of pages | 5 |
| Journal | Infection and Drug Resistance |
| Volume | 14 |
| DOIs | |
| Publication status | Published - 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cryptococcosis
- Janus kinase inhibitor
- Pleural effusion
- Primary myelofibrosis
- Ruxolitinib
- Treatment
- Tuberculosis
Fingerprint
Dive into the research topics of 'Combined pulmonary tuberculosis with pulmonary and pleural cryptococcosis in a patient receiving ruxolitinib therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver